Suppr超能文献

烯二炔类抗肿瘤抗生素C-1027生物合成中含4-亚甲基咪唑-5-酮的酪氨酸氨基变位酶的动力学分析。

Kinetic analysis of the 4-methylideneimidazole-5-one-containing tyrosine aminomutase in enediyne antitumor antibiotic C-1027 biosynthesis.

作者信息

Christenson Steven D, Wu Weiming, Spies M Ashley, Shen Ben, Toney Michael D

机构信息

Department of Chemistry, University of California-Davis, 95616, USA.

出版信息

Biochemistry. 2003 Nov 4;42(43):12708-18. doi: 10.1021/bi035223r.

Abstract

The enediyne antitumor antibiotic C-1027 contains an unusual (S)-3-chloro-4,5-dihydroxy-beta-phenylalanine moiety, which requires an aminomutase for its biosynthesis. Previously, we established that SgcC4 is an aminomutase that catalyzes the conversion of L-tyrosine to (S)-beta-tyrosine and employs 4-methylideneimidazole-5-one (MIO) at its active site [Christenson, S. D., Liu, W., Toney, M. D., and Shen, B. (2003) J. Am. Chem. Soc. 125, 6062-6063]. Here, we present a thorough analysis of the properties of SgcC4. L-Tyrosine is the best substrate among those tested and most likely serves as the in vivo precursor for the (S)-3-chloro-4,5-dihydroxy-beta-phenylalanine moiety. The presence of MIO in the active site is supported by several lines of evidence. (1) Addition of ATP or divalent metal ions has no effect on its aminomutase activity. (2) SgcC4 has optimal activity at pH approximately 8.8, similar to the pH optima of MIO-dependent ammonia lyases. (3) SgcC4 is strongly inhibited by sodium borohydride and potassium cyanide, but preincubation with L-tyrosine or 4-hydroxycinnamate largely prevents this inhibition. (4) The difference spectrum between SgcC4 and its S153A mutant shows a positive peak at approximately 310 nm, indicative of MIO. (5) The S153A mutation lowers k(cat)/K(M) 640-fold. The SgcC4-catalyzed conversion of L-tyrosine to (S)-beta-tyrosine proceeds via 4-hydroxycinnamate as an intermediate. The latter also acts as a competitive inhibitor with respect to L-tyrosine and serves as an alternative substrate for the production of beta-tyrosine in the presence of an amino source. A full time course for the SgcC4-catalyzed interconversion between L-tyrosine, beta-tyrosine, and 4-hydroxycinnamate was measured and analyzed to provide estimates for the rate constants in a minimal mechanism. SgcC4 also exhibits a beta-tyrosine racemase activity, but alpha-tyrosine racemase activity was not detected.

摘要

烯二炔类抗肿瘤抗生素C-1027含有一个不寻常的(S)-3-氯-4,5-二羟基-β-苯丙氨酸部分,其生物合成需要一种氨基变位酶。此前,我们确定SgcC4是一种氨基变位酶,可催化L-酪氨酸转化为(S)-β-酪氨酸,并在其活性位点使用4-亚甲基咪唑-5-酮(MIO)[克里斯滕森,S.D.,刘,W.,托尼,M.D.,和沈,B.(2003年)《美国化学会志》125,6062 - 6063]。在此,我们对SgcC4的性质进行了全面分析。L-酪氨酸是所测试底物中最佳的,最有可能作为(S)-3-氯-4,5-二羟基-β-苯丙氨酸部分的体内前体。活性位点中MIO的存在得到了多条证据的支持。(1)添加ATP或二价金属离子对其氨基变位酶活性没有影响。(2)SgcC4在pH约8.8时具有最佳活性,类似于依赖MIO的氨裂解酶的最适pH。(3)SgcC4受到硼氢化钠和氰化钾的强烈抑制,但与L-酪氨酸或4-羟基肉桂酸预孵育可在很大程度上防止这种抑制。(4)SgcC4与其S153A突变体之间的差光谱在约310nm处显示一个正峰,表明存在MIO。(5)S153A突变使k(cat)/K(M)降低640倍。SgcC4催化的L-酪氨酸向(S)-β-酪氨酸的转化通过4-羟基肉桂酸作为中间体进行。后者相对于L-酪氨酸也作为竞争性抑制剂,并在存在氨基源的情况下作为生产β-酪氨酸的替代底物。测定并分析了SgcC4催化的L-酪氨酸、β-酪氨酸和4-羟基肉桂酸之间相互转化的完整时间进程,以提供最小机制中速率常数的估计值。SgcC4还表现出β-酪氨酸消旋酶活性,但未检测到α-酪氨酸消旋酶活性。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验